Back to results
US 2012/0258039 A1Published application
Treatment of tumors using specific anti-l1 antibody
AssigneesMediGene AG, Deutsches Krebsforschungszentrum Stiftung des Offentlichen Rechts
InventorsDaniela Gast, Peter Altevogt, Gerhard Moldenhauer, Frank Brietling, Achim Krüger, Silke Wolterink, Sandra Lüttgau, Ulrich Mõbius, Yi Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to the anti-L1 monoclonal antibody 9.3 as well as to related antibodies or binding molecules and well as to the uses thereof, especially in tumor treatment.
Claims19
-30. (canceled)
A method for treating a tumorigenic disease, wherein an antibody or binding molecule selected from the group consisting of
- i) an anti-L1 monoclonal antibody which is capable of binding to the same L1 epitope recognized by the monoclonal antibody 9.3, produced by the hybridoma cell deposited under DSMZ ACC2841,
- ii) an anti-L1 monoclonal antibody, having the same capacity to inhibit tumor growth as the monoclonal antibody 9.3, produced by the hybridoma cell deposited under DSMZ ACC2841;
- iii) an anti-L1 monoclonal antibody, characterized in that at least one of its complementarity determining regions (CDRs)
- a) has one of the following sequences:
- RASQDISNYLN, YTSRLHS, QQGNTLPWT, RYWML, EINPRNDRTNYNEKFKT, or GGGYAMDY or
- b) has a sequence which, in comparison to the sequences mentioned under a) has at least one conservative amino acid exchange;
- iv) a monoclonal antibody, produced by the hybridoma cell deposited under DSMZ ACC2841;
- or
- v) a binding molecule comprising
- a) at least one of the following sequences RASQDISNYLN, YTSRLHS, QQGNTLPWT, RYWML, EINPRNDRTNYNEKFKT, or GGGYAMDY or
- b) at least one sequence which has in comparison to the sequences given in a) at least one conservative amino acid exchange.
- is administered to a subject in an effective amount to treat said disease.
9 more elements
Dependencies are inferred from the claim text.